FDA-AACR-IASLC Workshop to Address the Criticality of Tobacco Use Assessment in Oncology Therapeutic Trials
February 28, 2020 | Silver Spring, MD

Workshop Cochairs

Roy S. Herbst, MD, PhD, Yale Comprehensive Cancer Center

Dr. Roy Herbst is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine, New Haven, CT.

Dr. Herbst has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials testing these agents in advanced stage lung cancers. This work led to the approval of several therapies (such as Gefitinib, Cetuximab, Bevacizumab, Axitinib, Atezolizumab, and Pembrolizumab), which have revolutionized the field and greatly enhanced patient survival. His work on “umbrella” trials has galvanized the field of targeted therapy and cancer drug approvals at the FDA. Nationally, he is at the forefront of personalized medicine and works closely with public-private partnerships to develop large clinical studies, such as Lung-MAP. He testified on this before the House of Representatives 21st Century Cures committee and served as a prominent figure in this area as a member of the NAM Policy forum for 9 years. The NCI Lung SPORE he leads has identified new mechanisms of sensitivity and resistance to immunotherapy. Dr. Herbst is a highly respected clinician-scientist who has been a champion of translational medicine for decades, recently authoring a high-profile review of the 20-year progress in lung cancer. He has also been a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes), authoring multiple policy statements and leading frequent Capitol Hill briefings.

Dr. Herbst has authored or co-authored more than 300 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and the New England Journal of Medicine. Work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum.

Dr. Herbst was a member of the National Cancer Policy Forum, for which he organized an IOM meeting focused on policy issues in personalized medicine. He is a member of the American Association of Cancer Research, where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. He is vice chair for developmental therapeutics for Southwestern Oncology Group’s (SWOG) Lung Committee. In 2015, his team at Yale was awarded a Lung Cancer SPORE by the NCI, and he serves as a principal investigator for a AACR/Stand Up to Cancer Dream Team grant.

For his lifetime achievement in scientific contributions to thoracic cancer research, Dr. Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the International Association for the Study of Lung Cancer at IASLC 17th World Conference on Lung Cancer in Vienna, Austria.
Michael E. Menefee, MD, U.S. Food and Drug Administration

Dr. Menefee is a medical oncologist on the thoracic and head and neck malignancies team in the Office of Hematology and Oncology Products. He earned his medical degree from Meharry Medical College and completed a residency in internal medicine at the Mayo Clinic. He went on to complete his fellowship training in oncology and hematology at the National Cancer Institute. Prior to joining the FDA in 2018, Dr. Menefee served as an assistant professor of oncology at Mayo Clinic for 11 years. His clinical focus was on thoracic and endocrine malignancies and served as a clinical investigator on numerous clinical trials. During his tenure at Mayo Clinic, Dr. Menefee also served as a permanent member of the FDA Oncologic Drug Advisory Committee.

Matthew Steliga, MD, Winthrop P. Rockefeller Cancer Institute

Dr. Steliga is a thoracic surgeon specializing in thoracic oncology with an emphasis on lung cancer, and esophageal cancer. Dr. Steliga completed his training in 2009 and served as an instructor in the Department of Thoracic and Cardiovascular Surgery at M. D. Anderson Cancer Center in Houston. He has spent the past eleven years with the University of Arkansas for Medical Sciences (UAMS) and is currently the chief of the division of Thoracic Surgery. Dr. Steliga helped to develop lung cancer screening at UAMS and is the collaborative physician lead for the smoking cessation program at UAMS. He has been actively involved in the IASLC and is the current chair of the IASLC Tobacco Control and Smoking Cessation Committee.

Workshop Speakers and Panelists

Sundeep Agrawal, MD, U.S. Food and Drug Administration

Dr. Sundeep Agrawal is a board certified medical oncologist and current medical officer at the FDA’s Center for Drug Evaluation and Research, Division of Oncology. He completed his residency training at Drexel University College of Medicine in 2012 and completed fellowship in hematology and oncology at Washington Hospital Center/Georgetown University Hospital in 2016. He joined the FDA in September 2016. His area of focus is genitourinary cancers.

Linda Bailey, JD, MHS, North American Quitline Consortium

Linda Bailey, JD, MHS, is founder and CEO of the North American Quitline Consortium. The Consortium is a membership organization that aims to maximize the access, use and effectiveness of tobacco cessation services offered through quitlines in the U.S. and Canada.

Linda has a notable career in public health as an attorney, educator, and epidemiologist and a strong professional interest in influencing the development of science-based policies that promote health. Prior positions have included director, Center for Tobacco Cessation (at the American Cancer Society), associate director for the Center for Disease Control and Prevention’s Office on Smoking and Health in Washington, D.C. (U.S. Department of Health and Human Services), senior advisor on health promotion and disease prevention at the Office of the Assistant Secretary of Health (HHS), study director at the Institute of Medicine, and epidemiologist at the Houston Health Department. She was also a faculty member at Johns Hopkins School of Public Health and the University of Maryland School of Law. Linda holds a bachelor’s degree from Tufts University, a master’s degree from Johns Hopkins School of Hygiene and Public Health and a law degree from the University of Maryland School of Law.
Laura Bierut, MD, Washington University School of Medicine

As a physician scientist, Dr. Bierut has built a successful research program devoted to understanding the genetics of nicotine use disorder. She served on the Advisory Counsel for the National Institute on Drug Abuse (NIDA) and she is an active member of the NIDA Genetics Consortium, a group of scientists leading NIDA’s efforts to understand genetic causes of substance dependence. She currently is a member of the FDA’s Tobacco Products Scientific Advisory Committee, and she is co-chair of the National Comprehensive Cancer Network Smoking Cessation Guidelines workgroup. Dr. Bierut led the initial studies that found that the α5 nicotinic receptor subunit gene on chromosome 15 increase a smoker’s risk for nicotine use disorder. These same genetic variants that contribute to heaviness of smoking are the strongest genetic influences on the development of lung cancer. As an active clinician, she is consistently recognized as one of the Best Doctors in our region, and her goal is to capitalize on discoveries and carry them through to improving treatment for our patients and population health.

Paul A. Bunn, Jr, MD, FASCO, FACP, FAAAS, University of Colorado Cancer Center

Dr. Bunn is Distinguished Professor and James Dudley Chair at the University of Colorado Cancer Center. He received his BA from Amherst College and MD from Weill Cornell Medical College. He completed an internship and residency at UCSF and fellowship in medical oncology at the US NCI. He served as section head of the NCI-Navy Medical Oncology branch from 1975-1984, Head of the Division of Medical Oncology at the Univ. of Colorado from 1984-1992. He was Director of the Univ. of Colorado Cancer Center from 1986-2009. In the IASLC, Dr. Bunn served on the Board of Directors from 1988 to 1994, President from 1997-2000, and CEO from 2004-2014. Dr. Bunn served on the Board of the ASCO from 1995-1999 and President from 2002-2003. Dr. Bunn has received the Karnofsky award from ASCO, the Hansen Merit award from the IASLC, the Sewall award from the Univ. of Colorado, PHS Medal of Commendation, among many other awards. The author of hundreds of articles, reviews and book chapters, Dr. Bunn’s research is well known in the cancer world focusing on novel therapies for lung cancer. From 1992 to 2019 he was the Principal Investigator on the Specialized Program in Research Excellence in Lung Cancer (SPORE) grant funded by the NCI to expand understanding about the biology of the disease, as well as to find new methods of diagnosis, prevention and treatment. Dr. Bunn has led numerous national and local trials regarding the treatment of lung cancer, and his findings are credited with setting standards in the treatment of the disease.

Priscilla Callahan-Lyon, MD, U.S. Food and Drug Administration

Dr. Priscilla Callahan-Lyon is an internist and pulmonologist. After 20 years of private medical practice, she joined FDA in 2008 as a medical reviewer in Center for Drug Evaluation and Research where she worked extensively on nicotine replacement therapies. She moved to the newly formed Center for Tobacco Products in 2012 and currently serves as Acting Director for the Division of Individual Health Science in the Center’s Office of Science. Dr. Callahan is part of several cross-center groups within FDA that are involved with nicotine policy and regulation including the Nicotine Steering Committee. She also serves as the FDA contact on the Tri-Agency workgroup (CDC, NIH, and FDA) focusing on smoking cessation.
Srikumar Chellappan, PhD, Moffitt Cancer Center

Dr. Srikumar Chellappan is the Chair of the Department of Tumor Biology at the H. Lee Moffitt Cancer Center and Research Institute at Tampa, Florida. Dr. Chellappan obtained his PhD in Biochemistry from the Indian Institute of Science, Bangalore, India and did his post-doctoral training at Duke University Medical Center, Durham, NC. After being an Assistant Professor in the Department of Pathology at Columbia University in New York from 1992-2001, he joined Moffitt Cancer Center, where he is a tenured Professor and Senior Member. He was recognized as a Moffitt Distinguished Scholar in 2015. Dr. Chellappan’s research interests include signal transduction and transcriptional regulation, especially in the context of nicotine and smoking, cancer stem cells, tumor progression and metastasis.

His laboratory has focused on how activation of nicotinic acetylcholine receptors affect the response of lung and pancreatic cancers to therapy. His research has been continuously funded since 1994 and his work has been published in journals like Nature Communications, PNAS, Journal of Clinical Investigation, JNCI, Stem Cells, Cancer Research etc. He is currently Molecular Cancer, Neoplasia and PLoS one, and has also served on more than one hundred NIH study sections and review panels of national agencies.

Fumiko Chino, MD, Memorial Sloan Kettering Cancer Center

Fumiko Chino, MD, is a cancer researcher and Assistant Attending in Radiation Oncology at Memorial Sloan Kettering Cancer Center. Her research is focused on the financial toxicity of cancer care, health care disparities and access, patient reported outcomes, shared decision making, survivorship and end-of-life care. Her work has been published in *JAMA Oncology*, *Cancer*, the *American Journal of Managed Care*, and the ASCO Education Book. Her commentary on health care reform and cancer care has been featured in *JAMA Oncology*, *The Los Angeles Times* and *The Conversation*. Her work has been covered by national news media outlets including *The New York Times*, *Forbes*, and NPR. She graduated medical school (Alpha Omega Alpha) and completed residency at Duke School of Medicine (Chief Resident). She also served as the Teaching Value Fellow at the Costs of Care group, a global NGO focused on affordability in health care. She has received research support from the Chanel Foundation and the Radiation Oncology Institute. She has spoken across the US and internationally on the costs of cancer care.

Carolyn Dresler, MD, MPA

Carolyn Dresler, MD, MPA, was trained at Memorial Sloan Kettering and the University of Toronto as a thoracic surgical oncologist with clinical practices at Washington University and Fox Chase Cancer Center. She retired in 2018 as the Associate Director for Medical and Health Sciences for the Office of Science at the Center for Tobacco Products within the FDA. Prior to this she was the Director for the Arkansas Department of Health Tobacco Prevention and Cessation Program. Before Arkansas, she was the Head of Unit for Tobacco and Cancer at the International Agency for Research on Cancer in Lyon, France. In 2002-2003 she completed a Master in Public Administration at the Kennedy School of Government at Harvard University with an independent study in the human rights based approach to tobacco control. Her goal is to have fewer people dying from tobacco, specifically from tobacco-caused lung cancer.

Naomi Horiba, MD, MPH, U.S. Food and Drug Administration

Naomi Horiba, MD, MPH, is a graduate of Tulane University Medical School where she also completed her public health degree and residency training in internal medicine. She performed her medical oncology and hematology training at the University of Maryland Marlene and Stewart Greenebaum Cancer Center and continued on as a faculty member for 6 years, subspecializing in gastrointestinal malignancies. During that time, she participated in and co-authored numerous multicenter clinical trials. She maintains board certification in internal medicine and medical oncology. In 2015, Dr. Horiba...
joined the U.S. Food and Drug Administration’s Office of Hematology and Oncology Products (now the Office of Oncology Drugs) as a medical officer and is currently serving as the scientific liaison for gastroesophageal and hepatobiliary malignancies.

**Adnan Jaigirdar, MD, U.S. Food and Drug Administration**

Dr. Jaigirdar currently is an Acting Team Leader for the Thoracic, Head and Neck Oncology Team in the Division of Oncology 2, OOD, CDER, FDA.

He completed his surgical oncology training at NCI, and prior to joining the FDA in 2016, Dr. Jaigirdar was a surgical oncologist at the Walter Reed National Military Medical Center, Fort Belvoir, and a Clinical Assistant Professor of Surgery at the Uniformed Services University of the Health Science (USUHS). For the past few years at the FDA, his work has been focused in the review of investigational biologic and combination advanced therapies, including cell and gene therapies, in solid tumors.

**Paul Kluetz, MD, U.S. Food and Drug Administration**

Paul Kluetz is a medical oncologist and Deputy Director of the Oncology Center of Excellence (OCE) at the U.S. FDA. His interests include trial design and endpoint selection to expedite drug development and define clinical benefit in oncology trials. His work has included the initiation and direction of the OCE’s patient-focused drug development program. This program has been instrumental in leading FDA’s efforts to review, analyze and communicate clinical outcome information from patient reported outcomes (PRO), wearable technologies, and other methods to measure symptoms and function in both the clinical trial and “real-world” settings. He has also worked to advance patient-friendly trial designs including pragmatic and decentralized trials, as well as contributed to broader FDA efforts to expand trial eligibility criteria. In addition, Dr. Kluetz is leading Project Renewal, an OCE pilot project developing a systematic process to review accumulated evidence in order to update the product labels of longstanding cancer therapies. Dr. Kluetz remains clinically active, caring for patients and supervising medical residents at the Georgetown University Hospital.

**Stephanie Land, PhD, National Cancer Institute**

Stephanie Land is a Program Director and Statistician in the Behavioral Research Program Tobacco Control Research Branch (TCRB) at the National Cancer Institute (NCI), with a secondary appointment in the NCI Coordinating Center for Clinical Trials. Her areas of focus are tobacco use among patients in the settings of cancer prevention, screening, treatment, and survivorship. She is a member and past chair of the Division of Cancer Control and Population Science Clinical Trials Coordination Group and the NCI Clinical Trials Stewardship Committee. Formerly, she was a member of the NCI Special Studies Institutional Review Board, Associate Editor for the Journal of Clinical Oncology, and a member of the CPCRN Tobacco/Lung Cancer Working Group, and chair of the NCI-AACR Cancer Patient Tobacco Use Assessment Task Force.

She serves on the American Association for Cancer Research (AACR) Tobacco and Cancer Subcommittee and is a member of the National Lung Cancer Roundtable. She is the NCI lead for the Smoking Cessation At Lung Examination (SCALE) Collaboration, a collaboration that will share data and methods across eight funded projects to pursue research on cessation interventions that are efficacious and feasible in lung cancer screening clinics. She is also the NCI lead for the Cancer Center Cessation Initiative (C3I).

Before joining NCI in 2011, Dr. Land was an Associate Professor of Biostatistics at the University of Pittsburgh. From 1999-2011, she was a statistician in the National Surgical Adjuvant Breast and Bowel Project (NSABP), an NCI-funded clinical trials cooperative group that conducted multi-center phase III trials for breast and colorectal cancer. She also collaborated
with members of the University of Pittsburgh Cancer Institute Lung and Thoracic Malignancies Program from 1999-2011 and served as the lead statistician for the Lung Cancer Specialized Program of Research Excellence (SPORE) from 2002-2011. Dr. Land earned a doctorate in statistics from Stanford University.

Shakun Malik, MD, National Cancer Institute

Shakun Malik is Head, Thoracic Cancer Therapeutics, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment & Diagnosis, National Cancer Institute (NCI). She joined the CTEP in November 2013. Her goal is to facilitate lung cancer research. Prior to joining CTEP, Dr. Malik worked at the U.S. Food and Drug Administration (FDA), where she gained valuable experience in understanding the regulatory pathways that make drugs available to patients.

Dr. Malik has extensive clinical background. She currently performs clinical work one day a week at the NCI Clinical Center, and has worked as an Associate Professor of Medicine in the Department of Hematology/Oncology at the Georgetown University Hospital. She has served as the Chief of Center for Thoracic Oncology and Director of Multi-Disciplinary Thoracic Oncology Clinic at the Lombardi Cancer Center, and also worked as an associate in a Phase I program of drug and developmental therapeutics.

Dr. Malik graduated from of The University of Kashmir, India, and completed her hematology/oncology fellowship at The George Washington University and conducted research with the Human Genome project at the National Institutes of Health. She is also triple boarded by the American Board of Internal Medicine (Internal Medicine/Oncology and Hematology).

Dr. Malik has multiple publications in peer-reviewed journals. She has presented the FDA’s work in multiple scientific seminars and co-chaired a Joint NCI Thoracic Malignancies Steering Committee-FDA Workshop “Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer” in February 2012. Dr. Malik's interests focus on lung cancer and the development of new markers and therapeutic options for this disease.

Glen D. Morgan, PhD, National Cancer Institute

Glen Morgan, PhD, is currently a scientific consultant in Vienna Virginia and Adjunct Professor in the Department of Family Medicine at the University of North Carolina. He was a senior scientist in the Tobacco Control Research Branch at the National Cancer Institute as a Clinical Psychologist and Program Director from 1998-2019. Prior to joining NIH, he was the Director of Behavioral Sciences and Research at the Wyoming Valley Family Practice Residency and a Clinical Assistant Professor of Family and Community Medicine at the Milton Hershey College of Medicine of the Pennsylvania State University. He received his doctorate in Clinical Psychology at Washington University in St. Louis (1983).

Dr. Morgan was the lead Program Official for the Transdisciplinary Tobacco Use Research Centers (P50) since its inception in 1999 and co-directed NCI's Tobacco Intervention Research Clinic. He has served as Associate Editor, American Journal of Health Behavior for over 20 years. Dr. Morgan was formerly the lead scientific officer on the NCI Cancer Centers Smoking Cessation Initiative, funding over 40 supplements to enhance and expand the delivery of smoking cessation treatments to cancer patients and survivors. Dr. Morgan's research has centered on smoking interventions in primary care, cessation among chronically diseased patients, informatics and digital solutions for health behavior change, and interdisciplinary research in the treatment of tobacco use and nicotine addiction.

@FDAOncology  @AACR  @IASLC

Join the conversation with #OCETobaccoUse
James Pantelas, Patient Advocate

James (Jim) Pantelas is a 14-year, late stage lung cancer survivor, veteran, and an active patient advocate. He serves on multiple boards and committees for health care and research organizations, providing his perspective as a patient and caregiver. Among other initiatives, he has contributed to hospitals’ efforts to improve patient- and family-centered care and has developed training to enhance patient and family member participation in medical research.

Jim is a former IT executive and workaholic who now spends his time actively advocating for more research funding, and for expanding the use of big data in the study of lung cancer causes, risk factors, prevention and treatment.

Elyse Park, PhD, Harvard Medical School

Dr. Park is clinical health psychologist and health services researcher. An Associate Professor in Psychiatry Medicine at Mass General Hospital in Boston, her research is conducted at the MGH Mongan Institute for Health Policy Research Center. She has dual leadership roles directing the behavioral science research at the MGH Cancer Center’s Survivorship Program and the MGH Tobacco Research & Treatment Center. She has extensive experience developing and assessing smoking cessation counseling interventions for patients at risk for cancer, cancer patients, and cancer survivors, as well as delivering telehealth-delivered behavioral interventions. She is the PI of two NCI funded trials integrating tobacco treatment into the care of newly diagnosed patients at NCI affiliated cancer centers (NCORP) and into the lung cancer screening process. As a recent recipient of an NCI K24 mentoring award, she conducts research, and mentors junior Medicine trainees and faculty, on integration of tobacco treatment interventions into clinical care. She serves on the steering committee for the NCI’s Smoking Cessation Initiatives at NCI Cancer Centers, ASCO’s Tobacco Treatment Taskforce, and is writing member for the NCCN’s Smoking Cessation Guidelines Panel. She co-chairs the ECOG-ACRIN Health Promotion Subcommittee within the Cancer Control and Survivorship Committee, with the goal of advancing a program of health promotion and tobacco cessation research within the National Clinical Trials Network.

Cathy Pietanza, MD, Merck

Dr. Maria Catherine (Cathy) Pietanza attended the College of Arts and Sciences at New York University, where she graduated with a Bachelor of Arts in Chemistry and Italian. Cathy received her medical degree from The State University of New York Health Science Center at Brooklyn/Downstate in Brooklyn, New York in 2001. She completed her residency in Internal Medicine at New York Presbyterian Hospital/Weill Cornell Medical Center, and fellowship in Medical Oncology and Hematology at Mount Sinai School of Medicine, where she was also a chief fellow.

Upon completing fellowship in 2007, she was appointed as an Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, where her primary clinical responsibility was in thoracic oncology, and as an Assistant Professor of Medicine at Weill Cornell Medical College. At Memorial Sloan Kettering Cancer Center, Cathy led the Small Cell Lung Cancer Research Program, and was a principal and co-principal investigator on clinical trials in small cell and non-small cell lung cancer, as well as pulmonary neuroendocrine tumors. She completed several investigator initiated trials and company sponsored clinical studies. Cathy developed a comprehensive program for prospective molecular profiling of small cell lung cancer patients undergoing treatment, in an attempt to better understand the molecular mechanisms of this disease and develop more effective therapeutic strategies. One additional aspect of her research was to evaluate the importance of utilizing patient-reported outcomes in clinical trials to guide symptom management. She has coauthored numerous articles, reviews, and book chapters, published in such journals as the Journal of Clinical Oncology, Clinical Cancer Research, Nature Genetics, and Cancer and has been an invited lecturer and presenter at national and international meetings.

Join the conversation with #OCETobaccoUse
In January 2016, she joined Merck Research Laboratories within the Global Center of Scientific Affairs as Global Director, Scientific Affairs for Oncology, where she led the Merck Investigator Initiated Studies Program for Oncology and assisted in executing the Oncology Scientific Leadership Strategy. Following her passion to conduct clinical research, she changed her role at Merck in April 2018 and has been responsible for the development and implementation of several phase III trials utilizing the immune checkpoint inhibitor, pembrolizumab (Keytruda®). In November 2018, she became the Product Development Team Lead for Keytruda in Thoracic Malignancies, leading a program and series of studies in several lung cancers, as well as the strategy for pembrolizumab and other products in these diseases.

Cathy is a member of IASLC, ASCO, ESMO, AACR, and ACP. In her free time, Cathy enjoys spinning, skiing, traveling and spending time with her baby niece.

Harpreet Singh, MD, *U.S. Food and Drug Administration*

Harpreet Singh is the Director (Acting) of the Division of Oncology 2 with the Office Oncologic Diseases at FDA. Her Division regulates thoracic, head and neck cancers, neuro-oncology, rare tumors, and pediatric solid tumors. Dr. Singh received her M.D. degree from the University of Southern California. She completed her Internal Medicine residency and geriatrics fellowship at USC, followed by a Medical Oncology fellowship a the National Cancer Institute. Dr. Singh has also served as the Scientific Liaison for Cancer in Older Adults since 2016. Since joining the Agency, Dr. Singh has expertly engaged with the greater scientific community, chairing public workshops on Cancer in Older Adults, and Adjuvant Bladder and Renal Cell Clinical Trials. She has consistently presented original FDA research at major conferences, and published in peer reviewed journals such as the Journal of Clinical Oncology (JCO). Twitter handle: @harpreet_md

Nichelle Stigger, *Patient Advocate*

Nichelle Stigger was born in Kalamazoo, Michigan, and raised in Oak Park. She resides with her younger son Parker Stigger and Husband Aaron Stigger. Nichelle’s first passion is education and is currently a 6th grade Language and Literature teacher in Oak Park. She believes that knowledge can be a place of enlightenment, and teaches her kids to practice leading with love in all interactions.

Nichelle Stigger was diagnosed in 2017 with the rarest type of lung cancer, Mucinous Adenocarcinoma, and is a 3-year lung cancer survivor. She says that having lung cancer has opened many doors and has allowed her to live life in the most full way she can. She has made it her fight to educate, facilitate, engage, and organize those in powerful positions to bring about change in the pursuit of equity for all. In her spare time, Nichelle enjoys her family, listening to podcasts, writing for her Master Class, building masterpieces out of legos with her son, and reading poetry.

Brenna Van Frank, MD, MSPH, *Centers for Disease Control and Prevention*

Dr. Brenna VanFrank, MD, MSPH, is the senior medical officer in the Office on Smoking and Health (OSH) at the Centers for Disease Control and Prevention (CDC). She is responsible for providing input on the medical aspects of OSH’s scientific research and communications and serves as a scientific and medical consultant for programs and projects. She has particular interest in the integration of healthcare and public health and the use of epidemiologic data for public health action. Dr. VanFrank joined CDC in 2014 as an Epidemic Intelligence Service (EIS) officer, and has worked on a variety of public health topics. Dr. VanFrank received her BS and MSPH from the University of Utah and her MD from the University of Wisconsin. She is board certified in pediatrics and preventive medicine and is a member of the national Delta Omega Honorary Society in public health.
Graham Warren MD, PhD, is a Bard Certified Radiation Oncologist, Professor, and Vice Chairman for Research in the Department of Radiation Oncology at the Medical University of South Carolina. His primary academic interest is in addressing the biologic, clinical, behavioral, and economic effects of tobacco use in cancer patients. He was a contributor for the 2014 and 2020 Surgeon General’s Reports on Tobacco having authored sections on the adverse effects of smoking on cancer treatment outcomes and benefits of smoking cessation after a cancer diagnosis. He has led development of several smoking cessation programs at institutional, state, and national levels and has worked with numerous cancer organizations including the NCI, ACS, AACR, ASCO, IASLC, SRNT and others to improve cancer treatment outcomes for cancer patients through tobacco control.